

Based on the analysis of the "ZYDUSLIFE.NS" PDF report (generated 2026-01-10), here is my assessment from the perspective of a positional equity trader.

### ### Step 1: Audit the Data

- \* \*\*Data Present:\*\*
  - \* Multi-timeframe price charts (Daily, Weekly, 15-min).
  - \* Key Moving Averages (EMA 20, 50, 200) and crossover status.
  - \* Momentum Indicators (RSI, MACD with Histogram).
  - \* Trend Indicators (Supertrend, Bollinger Bands).
  - \* Relative Strength (RS) analysis against Benchmark (^CNXPHARMA).
  - \* Volatility Analysis (Squeeze and ATR).
  - \* Basic Fundamental Snapshot (Revenue, ROE, Valuation scores).
- \* \*\*Data Missing:\*\*
  - \* \*\*Volume Profile / Delivery %:\*\* While daily volume bars are present, specific delivery data to confirm accumulation vs. intraday speculation is missing.
  - \* \*\*Fibonacci Retracements:\*\* No explicit retrace levels from the 2024 peak are drawn to identify major structural support.
- \* \*\*Confidence Level:\*\* \*\*High.\*\* The technical data is robust and covers all necessary aspects (trend, momentum, volatility, and relative strength) to make an informed technical decision.

### ### Step 2: Analyze the Setup

- \* \*\*Price Structure & Trend:\*\* The stock is in a \*\*Strong **Downtrend**\*\*. Price (894.90) is trading below the EMA 20 (917), EMA 50 (932), and EMA 200 (951). The alignment of EMAs (20 < 50 < 200) confirms a classic bearish "Death Cross" structure.
- \* \*\*Momentum & Volatility:\*\*
  - \* \*\*Volatility Squeeze:\*\* Page 14 indicates a \*\*Bearish Breakout\*\* from a volatility squeeze on 2026-01-09. This is a highly negative signal, suggesting the expansion of volatility is occurring to the downside.
  - \* \*\*Bollinger Bands:\*\* The price is "walking the bands" downward and is currently below the Lower Band (898.11), indicating extreme weakness.
  - \* \*\*RSI:\*\* RSI is at 35.71. While approaching oversold territory, it has not yet formed a convincing bullish divergence that has been confirmed by price action.
  - \* \*\*MACD:\*\* There is a faint bullish divergence noted on Page 12, but the histogram is weak, and the signal has not translated into a price reversal.
- \* \*\*Relative Strength:\*\* The stock has an RS Score of 45.7/100 and is labeled "Neutral" but lagging. It is underperforming the Pharma sector, which makes it a poor candidate for a long position in the current environment.

\*\*Conclusion on Setup:\*\* There is \*\*no confluence\*\* for a long entry at this moment. The stock is catching a falling knife. The bearish volatility breakout suggests the price could seek lower liquidity zones before stabilizing.

### ### Step 3: Formulate the Recommendation

\*\*Recommendation: NO\*\* (Do not enter at current market price).

\*\*Rationale:\*\* The stock has just triggered a fresh bearish volatility breakdown. Buying now fights the immediate momentum and three layers of overhead resistance (EMA 20, 50, and Supertrend).

\*\*Conditional Plan (Watchlist for Reversal):\*\*

Given the oversold nature (Price < Lower BB), a mean reversion trade is possible \*if\* momentum shifts. I would only consider a position if the stock reclaims immediate structural resistance.

- \* \*\*Condition to Buy:\*\* Price must close above the \*\*Supertrend Resistance (936)\*\* and the \*\*EMA 50 (932)\*\*. This invalidates the immediate downtrend and puts the price back into a neutral/bullish zone.
- \* \*\*Entry Price:\*\* \*\*INR 938 - INR 940\*\* (Wait for the daily close confirmation).
- \* \*\***Stop Loss**:\*\* \*\*INR 890\*\* (Hard stop below the recent swing low/current price consolidation).
- \* \*\***Take Profit**:\*\* \*\*INR 1,040 - INR 1,050\*\* (Targeting the previous breakdown level and EMA 200 overhead resistance).
- \* \*Risk/Reward Ratio:\* ~1:2.2 (Risking ~50 points to make ~110 points).
- \* \*Upside Potential:\* ~11.5% (Fits the 5-15% criteria).

## # News & Analyst Targets

Here is the latest research and information on \*\*Zydus Lifesciences (ZYDUSLIFE)\*\* for the week ending \*\*January 10, 2026\*\*.

### ### \*\*1) Latest News for ZYDUSLIFE (Week of Jan 5 - Jan 10, 2026)\*\*

The most significant development this week is a major regulatory win in the domestic diabetes market.

- \* \*\*CDSCO Panel Approval for Semaglutide (Jan 9, 2026):\*\*
  - \* Zydus Lifesciences has received a key recommendation from the \*\*Central Drugs Standard Control Organisation (CDSCO)\*\* Subject Expert Committee (SEC).
    - \* The panel cleared the company to manufacture and market \*\*Semaglutide Injection (15 mg/3 ml)\*\*, a synthetic GLP-1 receptor agonist used for the treatment of \*\*Type 2 Diabetes Mellitus\*\*.
    - \* This approval follows the acceptance of Zydus's Phase III clinical trial report. Semaglutide is a high-demand drug class (similar to Ozempic/Wegovy) globally known for weight management and metabolic control benefits.
- \* \*\*Upcoming FDA Catalyst (Scheduled for Jan 14, 2026):\*\*
  - \* Investors are closely watching the upcoming \*\*PDUFA (target action) date\*\* of \*\*January 14, 2026\*\*, for \*\*CUTX-101 (Copper Histidinate)\*\*.
    - \* The US FDA is reviewing the New Drug Application (NDA) resubmitted by Zydus's subsidiary, Sentyln Therapeutics, for this treatment of Menkes disease. A decision is expected next week.

### ### \*\*2) Brokerage Upgrades & Downgrades\*\*

Activity from brokerages has been mixed to neutral in recent months, with analysts focusing on the sustainability of US generics revenue.

- \* \*\*MarketsMojo (Dec 2025):\*\* Recently upgraded its technical evaluation of the stock to \*\*\*Mildly **Bullish**\*\*\* from a previous neutral/bearish stance, citing improved technical signals despite some pressure on operating margins.
- \* \*\*Consensus View (Late 2025):\*\* Most analysts have maintained a \*\*HOLD\*\* or \*\*NEUTRAL\*\* rating. The primary concern cited is valuation after the stock's significant run-up over the last two years and the high base of US sales (driven by products like Revlimid generics) which may normalize.

### ### \*\*3) Other News Impacting ZYDUSLIFE\*\*

- \* \*\*Recent US FDA Approvals (Q4 2025 Context):\*\* The company continues to expand its US portfolio, which provides a floor for revenue expectations.
  - \* \*\*Verapamil Hydrochloride ER Tablets:\*\* Received final approval in late November 2025 (Cardiac treatment).
  - \* \*\*Deflazacort Oral Suspension:\*\* Approved in October 2025 (Treats Duchenne Muscular Dystrophy), adding a niche product to their US basket.
- \* \*\*Biosimilar Expansion:\*\* The approval of Semaglutide is part of a broader strategy to capture the Indian chronic therapy market, reducing dependence on the volatile US generics market.

#### ### \*\*4) Latest Analyst Targets (2026 Outlook)\*\*

The consensus among the analyst community suggests limited immediate upside from current levels, with the stock trading near its fair value estimates.

Brokerage / Source	Rating / Stance	Target Price (INR)	Outlook / Notes
Alpha Spread Consensus**	Buy/Hold**	INR 1,035**	Average 1-year forecast. Bull case sees INR 1,376.
MarketScreener Consensus**	Hold**	INR 1,014**	Consensus average. Spread suggests tight valuation.
Simply Wall St**	Neutral**	INR 1,016**	Based on statutory earnings forecasts for FY26/27.
Nomura**	Neutral**	INR 1,020***	Maintained from previous update; wary of margin dip.*
Motilal Oswal**	Neutral**	INR 1,210***	Long-term constructive but valuations cap upside.*

\*\\*Note: Some specific brokerage targets are carried over from late 2025 reports as major updates are expected following the Q3 FY26 results usually released in February.\*

# Stock Detailed Analysis Report

**ZYDUSLIFE.NS**

Current Price: ₹894.90

Generated: 2026-01-10 10:19

# ZYDUSLIFE.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	18.68%	15.04%
Net Income	Yes	Yes	17.26%	0.28%
ROE	No	Yes	-2.93%	-10.55%
EPS	Yes	Yes	17.91%	0.86%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	2.81%	2.59%
Net Income	Yes	25.27%	4.04%
ROE	Yes	17.08%	17.08%
EPS	No	12.25%	-11.77%

# ZYDUSLIFE.NS - Relative Strength Analysis

## == OVERVIEW ==:

**Benchmark Index:** ^CNXPHARMA

**Sector:** Pharma

**Classification:** Neutral

**RS Score:** 45.7/100

:

## == RS RATIOS ==:

**1M RS:** 0.960 [Neutral]

**3M RS:** 0.857 [Neutral]

**6M RS:** 0.900 [Neutral]

**1Y RS:** 0.954 [Neutral]

:

## == TURNAROUND ANALYSIS ==:

**Turnaround Status:** Not Detected

:


## SIGNAL CRITERIA::

✓ **Emerging RS:** 1M (0.960) > 3M (0.857)


✓ **Medium-term Lagging:** 6M=0.900, 1Y=0.954 ( $\leq 1.0$ )

✗ **Performance Improving:** Not improving


**Relative Strength Analysis: ZYDUSLIFE.NS vs ^CNXPHARMA**  
**Classification: Neutral**  
**Price Performance Comparison (Normalized)**



**RS Ratio Trends (Multiple Timeframes)**




**RS Composite Score Timeline**



## ZYDUSLIFE.NS - EMA Crossover Summary

<b>EMA 20:</b>	917.46
<b>EMA 50:</b>	932.45
<b>EMA 200:</b>	951.28
<b>Trend Status:</b>	<b>Strong Downtrend</b>

# ZYDUSLIFE.NS EMA Crossover Analysis



## ZYDUSLIFE.NS - Bollinger Bands Summary

<b>Current Price:</b>	894.90
<b>Upper Band:</b>	933.47
<b>Middle Band (SMA 20):</b>	915.79
<b>Lower Band:</b>	898.11
<b>%B:</b>	-0.0908
<b>Band Width:</b>	0.0386
<b>Status:</b>	Below Lower Band
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<a href="#">Buy Signal at 2025-11-07 00:00:00+05:30</a>
<b>Recent Signal 2:</b>	<a href="#">Buy Signal at 2025-12-18 00:00:00+05:30</a>


## ZYDUSLIFE.NS Bollinger Bands (20, 2) Analysis



## ZYDUSLIFE.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	935.99
Signal Identified On:	2025-09-26

### Supertrend Analysis for ZYDUSLIFE.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## ZYDUSLIFE.NS - MACD Summary

<b>MACD Line:</b>	-5.71
<b>Signal Line:</b>	-5.92
<b>Histogram:</b>	0.21
<b>Trend:</b>	<b>Bullish</b>
<b>Momentum:</b>	<b>Weakening</b>
<b>Signal:</b>	None
<b>Divergences Detected:</b>	1
└ <b>Bullish Divergence:</b>	Date: 2026-01-09 00:00:00+05:30, Price: 894.90

### ZYDUSLIFE.NS Price




### ZYDUSLIFE.NS MACD (12, 26, 9)



## ZYDUSLIFE.NS - Volatility Squeeze Summary

<b>BB Width:</b>	0.0386
<b>ATR:</b>	14.2571
<b>Total Signals:</b>	43
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2026-01-06 00:00:00+05:30 (Pr)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2026-01-07 00:00:00+05:30 (Pr)
<b>Signal 4:</b>	BB Squeeze + ATR Contraction at 2026-01-08 00:00:00+05:30 (Pr)
<b>Signal 5:</b>	<b>BB Squeeze (Bearish Breakout) at 2026-01-09 00:00:00+05:30</b>



## ZYDUSLIFE.NS - Volatility Squeeze Analysis



## ZYDUSLIFE.NS - RSI-Volume Summary

<b>Current RSI:</b>	35.71
<b>Current Volume:</b>	797148
<b>Volume MA 20:</b>	482356
<b>Bullish Divergences:</b>	6
<b>Bearish Divergences:</b>	3
<b>Bullish Div 1:</b>	Date: 2025-11-21 00:00:00+05:30, Price: 924.30
<b>Bullish Div 2:</b>	Date: 2025-12-18 00:00:00+05:30, Price: 913.65
<b>Bearish Div 1:</b>	Date: 2025-07-01 00:00:00+05:30, Price: 991.15
<b>Bearish Div 2:</b>	Date: 2025-09-18 00:00:00+05:30, Price: 1047.85

## ZYDUSLIFE.NS RSI-Volume Divergence Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	958.59	894.9	2025-11-03
1 Day	DOWNTREND (Sell)	935.99	894.9	2025-09-26
15 Min	DOWNTREND (Sell)	903.86	893.6	2026-01-07

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Weakening	No Signal

# ZYDUSLIFE.NS - 1 Week (Candlestick + EMAs)



# ZYDUSLIFE.NS - 1 Day (Candlestick + EMAs)



# ZYDUSLIFE.NS - 15 Min (Candlestick + EMAs)



## Trendlyne Snapshot - ZYDUSLIFE\_main

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#)  Search Stock, IPO, MF [India](#) A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUS LIFESCIENCES LTD.](#)

### Zydus Lifesciences Ltd. [①](#)

NSE: ZYDUSLIFE | BSE: 532321  
Zydus Lifesciences Live Share Price Today, Share Analysis and Chart

■ ■ ■ Mid-range Performer [①](#) [In 3 Starfolio Baskets](#)

**894.90** -12.65 (-1.39%)

**831.4K** NSE+BSE Volume  
NSE 09 Jan, 2026 3:31 PM (IST)

[Watchlist](#) [Portfolio](#) [Alert](#) [My Notes](#) [TRADE STOCK](#)

[Overview](#) [FORECASTER](#) [STOCK REPORT](#) [Buy Sell Zone](#) [F&O](#) [Financials](#) [News](#) [Reports](#) [Technicals](#) [Shareholding](#) [Deals](#) [Corporate Actions](#) [Alerts](#) [About](#)

Durability score [①](#) **65.0** /100 [Valuation Score](#) [①](#) **44.2** /100 [Momentum Score](#) [①](#) **42.5** /100 [Analyst Price Target](#) [①](#) **1,014** [1Yr Price target upside is 13%](#)

High Financial Strength [①](#) Mid Valuation [①](#) Technically Neutral [①](#)

Mid-range Performer These stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to i... [View Similar](#) [Embed DVM](#)

**Check Before You Buy** [VIEW FULL CHECKLIST](#)  
High rank **16** Positive **7** Negative **69.6% Pass in checklist**

**PE Valuation Check**  
Right Now [①](#) Undervalued **24.9%** [1 Year Forward](#) [①](#) Undervalued **15.9%**

**Zydus Lifesciences Key Metrics**

ROE Ann. % <a href="#">①</a> High in Industry	Broker Average Target <a href="#">①</a> 16.27% upside	Market Capitalization <a href="#">①</a> High in Industry	Price to Book <a href="#">①</a> Above Industry Median
<b>18.9</b>	<b>1,040.5</b>	<b>90,047.9</b>	<b>5.0</b>

DVM  
Key Metrics  
Price Chart  
Forecaster  
Financials  
Technicals  
Shareholding  
Deals  
Documents  
Corporate actions  
Company Profile X

## Trendlyne Snapshot - ZYDUSLIFE\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [More](#) [A](#)

Search Stock, IPO, MF [India](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [ZYDUSLIFE FORECASTER](#)

### Zydus Lifesciences Ltd. [①](#)

NSE: ZYDUSLIFE | BSE: 532321 [Mid-range Performer](#) [In 3 Starfolio Baskets](#)

Download real time STOCK REPORT

894.90 [-12.65 \(-1.39%\)](#)

831.4K NSE+BSE Volume  
NSE 09 Jan, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes TRADE STOCK

Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

### Zydus Lifesciences - ZYDUSLIFE - stock price prediction, stock forecast, target price, analyst ratings from 29 analysts

Zydus Lifesciences has a share price target of Rs 1014, revenue growth forecast of 10.8%, and profit growth estimate of 2.8% for FY26, based on top 29 analyst calls.

### Zydus Lifesciences FORECASTER - Analyst Estimates [②](#)

FORECASTER DASHBOARD [→](#)

